Trials / Enrolling By Invitation
Enrolling By InvitationNCT06312189
Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada
Open-Label Study of Valbenazine for the Treatment of Chorea Associated With Huntington Disease in Canada
- Status
- Enrolling By Invitation
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 7 (estimated)
- Sponsor
- Neurocrine Biosciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate long-term safety and tolerability of valbenazine in participants with chorea associated with Huntington Disease (HD) who participated in Study NBI-98854-HD3006 (NCT04400331) in Canada.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valbenazine | vesicular monoamine transporter 2 (VMAT2) inhibitor |
Timeline
- Start date
- 2024-04-24
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2024-03-15
- Last updated
- 2026-04-09
Locations
3 sites across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06312189. Inclusion in this directory is not an endorsement.